Market Place
Sourcing Support
Protagonist Therapeutics Reports Granting Of Inducement Awards
16 Apr 2026 //
PHARMIWEB
Protagonist Reveals 2025 Financials And Corporate Update
25 Feb 2026 //
PHARMIWEB
Protagonist Therapeutics to Attend Bank Conferences, March 2026
24 Feb 2026 //
PHARMIWEB
Protagonist`s $400M JPM26 Decision Is Total No-Brainer
16 Jan 2026 //
BIOSPACE
Protagonist Therapeutics to Attend 44th JPM Healthcare Conference
07 Jan 2026 //
PHARMIWEB
Protagonist Reveals Q3 2025 Financials & Corporate Update
06 Nov 2025 //
PHARMIWEB
J&J Eyes Takeover Of Immunology Partner Protagonist: WSJ
11 Oct 2025 //
FIERCE BIOTECH
Protagonist to Announce Oral Obesity Drug Candidate
26 Jun 2025 //
ACCESSWIRE
Protagonist Therapeutic at Jefferies Global Healthcare Conference
21 May 2025 //
ACCESSWIRE
Protagonist Reports Q1 2025 Financial Results and Corporate Update
06 May 2025 //
ACCESSWIRE
Protagonist Therapeutics on Fast Company`s 2025 Innovative List
18 Mar 2025 //
ACCESSWIRE
Protagonist, Takeda’s Rusfertide Ph 3 VERIFY Study Positive
03 Mar 2025 //
BUSINESSWIRE
Protagonist Therapeutics to Join Evercore ISI HealthCONx 2024 Conf
22 Nov 2024 //
ACCESSWIRE
Protagonist`s PN-881 as IL-17 Antagonist Development Candidate
21 Nov 2024 //
ACCESSWIRE
Protagonist Reports Q3 2024 Results & Update
07 Nov 2024 //
ACCESSWIRE
Protagonist Reports Q2 2024 Results And Provides Corporate Update
06 Aug 2024 //
ACCESSWIRE
Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress
14 Jun 2024 //
ACCESSWIRE
Protagonist At Jefferies Healthcare Conference 2024
31 May 2024 //
ACCESSWIRE
Protagonist Q1 2024 Results, Corporate Update
07 May 2024 //
ACCESSWIRE
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment
26 Mar 2024 //
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
06 Mar 2024 //
ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
20 Feb 2024 //
ACCESSWIRE
Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide
31 Jan 2024 //
ACCESSWIRE
Protagonist Therapeutics to Participate in 42nd Annual J.P. Morgan Conference
03 Jan 2024 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
16 Nov 2023 //
ACCESSWIRE
Protagonist Ranked in Top 3% of Fastest-Growing Companies in North America
09 Nov 2023 //
ACCESSWIRE
Protagonist Announces Abstracts Selected for Oral and Poster Presentations
02 Nov 2023 //
ACCESSWIRE
Protagonist Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
01 Nov 2023 //
ACCESSWIRE
Protagonist Announces Achievement of $50M Milestone Event
01 Nov 2023 //
ACCESSWIRE
Protagonist Announces Appointment of Daniel Swisher to Its Board of Directors
30 Oct 2023 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
03 Oct 2023 //
ACCESSWIRE
Protagonist Therapeutics to Present at Upcoming Investor Conferences
05 Sep 2023 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
16 Aug 2023 //
ACCESSWIRE
Protagonist Receives $34 Million from Warrant Exercises
09 Aug 2023 //
ACCESSWIRE
Protagonist Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
18 Jul 2023 //
ACCESSWIRE
J&J psoriasis drug licensed from Protagonist doesn`t top competition
03 Jul 2023 //
ENDPTS
Protagonist Announces Acceptance of Abstract for Oral Presentation at EHA
06 Jun 2023 //
ACCESSWIRE
Protagonist to Participate in the 2023 Jefferies Healthcare Conference
01 Jun 2023 //
ACCESSWIRE
Protagonist Therapeutics Announces Presentations at the 2023
11 May 2023 //
PR NEWSWIRE
Protagonist Therapeutics to Participate in the JMP Securities Life Conference
11 May 2023 //
PR NEWSWIRE
Protagonist Reports 1Q FYR 2023 and Provides Corporate Update
04 May 2023 //
PR NEWSWIRE
Protagonist Announces Pricing of $100 Million Public Offering of Shares
04 Apr 2023 //
ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
ACCESSWIRE
Protagonist`s story turns for the better on psoriasis data
08 Mar 2023 //
FIERCE BIOTECH
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan
21 Dec 2022 //
PRNEWSWIRE
Protagonist to Participate in the JMP Securities Hematology and Oncology Summit
01 Dec 2022 //
PRNEWSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
16 Nov 2022 //
PRNEWSWIRE
Drugs up for sale, on the shelf in biotech pipeline clear-outs
09 Nov 2022 //
FIERCEBIOTECH
Protagonist Therapeutics Announces Presentations at the ASH 2022 Meeting
03 Nov 2022 //
PRNEWSWIRE
Protagonist Announces Appointment of Arturo Molina as CMO
02 Nov 2022 //
PRNEWSWIRE
Protagonist Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
19 Jul 2022 //
PRNEWSWIRE
Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
01 Jun 2022 //
PRNEWSWIRE
Protagonist Reports First Quarter 2022 Financial Results
04 May 2022 //
PRNEWSWIRE
Not IDEAL: Protagonist sinks as oral Entyvio rival fails in IBD
26 Apr 2022 //
FIERCEBIOTECH
Protagonist Announces Topline Data from Phase 2 IDEAL Study of PN-943
25 Apr 2022 //
PRNEWSWIRE
Protagonist Therapeutics Reports Granting of Inducement Awards
19 Apr 2022 //
PRNEWSWIRE
